Perrigo announces summertime availability of desloratadine in Rx and OTC
ALLEGAN, Mich. — Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough’s Clarinex.
Under the terms of a patent-infringement suit settlement, Perrigo can commercially launch its generic desloratadine product July 1. The new product launch may be a prescription or over-the-counter product, depending on its status at the time of launch, Perrigo stated.
Clarinex sales were approximately $185 million, according to Perrigo, citing Wolters Kluwer data.
No comments found
Nutramax renews contract Cosamin spokesman Jim Palmer
EDGEWOOD, Md. — Nutramax Labs on Tuesday announced the continuation of its partnership with Major League Baseball’s Hall of Fame pitcher Jim Palmer in promoting Cosamin joint health supplements in national and regional marketing campaigns and events.
“We are pleased to enter into our 12th year of partnership with Jim Palmer,” stated Troy Henderson, VP corporate operations and professional services. "Palmer is an excellent [spokesman] for Cosamin joint health supplements because Cosamin is not just for athletes, but for anyone who is active.”
“Twelve years ago, my orthopedic doctor recommended Cosamin for my joint pain,” Palmer said. “I’ve been using it ever since — and at 65, I’m still very active and doing the things I love most since retiring from Major League Baseball in 1985.”
No comments found
Study: An aspirin a day adds to risk of age-related macular degeneration
SAN FRANCISCO — A large European study released Tuesday found that daily aspirin use is linked to an increased risk of age-related macular degeneration, a disease that can damage the central vision that is essential for reading and driving. The study was published in the January issue of Ophthalmology, the journal of the American Academy of Ophthalmology.
The study found that people aged 65 years and older who took aspirin daily had double the risk of developing "wet" AMD, compared with those who took it less frequently. Wet AMD, an advanced form of the disease, is a major cause of blindness in older people in the United States, Europe and other regions. The damage occurs when abnormal blood vessels grow and bleed or leak fluid into the macula, the center of eye’s retina. The study also found a somewhat elevated risk of early-stage AMD in daily aspirin users.
No higher risk was found for advanced "dry" AMD. Although dry AMD is the most common form of the disease, only a minority of patients develop the advanced stage. In those who do, vision loss occurs gradually as the macula develops abnormal deposits called drusen and eventually becomes too thin and eroded to function.
In this study, the 839 participants who reported taking aspirin every day had higher rates of cardiovascular disease, were less likely to be smokers and were older than participants who took aspirin less often. Since cardiovascular disease itself is a risk factor for AMD, the researchers carefully analyzed whether participants’ heart health had impacted the study’s outcomes. But even when cardiovascular status was factored in, the results showed higher risk for wet AMD in daily aspirin users, researchers noted.
The researchers said they think medical professionals should stick with their current advice on aspirin for older cardiovascular disease patients until other studies confirm the link between daily aspirin use and wet AMD risk.
"If future studies support our results, then recommendations on aspirin may need to be modified for patients with age-related macular degeneration," stated Paulus de Jong of the Netherlands Institute for Neuroscience and Academic Medicine, who led the research team. "It’s possible that increased AMD risk may outweigh aspirin’s potential protective benefits for some patients, but we need to know more about the impacts of dose, length of use and other factors before we can say for certain or make specific recommendations."
De Jong’s research was part of the European Eye Study that examined and surveyed more than 4,600 Europeans between 2000 and 2003. The study’s main goals were to estimate AMD prevalence and to investigate the impacts of sun exposure and antioxidant vitamin use on disease development.
Any medicine have a side effect when the usage of this is abused. Yes! many of us wanted to be cured but being cured for a short time and suffer for longer time, then I wont take the risk instead I will do proper diet exercise and natural methods for curing illness. Tyler, http://www.themiamiinjurylawyers.com/
Ed, Thank you for your response and I apologize for taking so long to get back to you — I needed to access the full study before I could reply. The researchers did not capture the actual strength of the aspirin in their poll. Of the 4,691 participants, when asked about their aspirin use, 2,760 replied never; 766 reported monthly or less; 326 at least once weekly; and 839 daily. From the Discussion portion of the research: There are no data regarding the amount of aspirin the participants used. In a meta-analysis of 31 trials including nearly 200,000 patients, however, daily aspirin intake of less than 100 mg was associated with bleeding, without mention of ocular hemorrhages, but with a lower risk than aspirin intake of 100 mg or more. In a study of AMD patients whose average aspirin intake was 100 mg/day, the [odds ratio] for severe subretinal hemorrhage was 7.99; so, one could extrapolate that our findings may even be explained by these low doses. I hope this helps! All the best! Mike
What asprin dosage was tested?? Huge missing data was 81mg baby asprin tested?? or 325mg ?? or WHAT ? Please advise [email protected]